Invion Ltd (ASX:IVX) chairman Thian Chew speaks with Proactive ahead of the Australian Microcap Investment Conference in Melbourne. IVX is a life-sciences company that is leading the global research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The company is progressing towards clinical trials as it completes the majority of the required pre-clinical studies and all drug discovery work for lead program INV043.
You can find out more about the 12th Annual Australian Microcap Investment Conference here: www.microcapconferences.com